Half Year Result 2016
CSL Delivers Exceptional Performance

Half Year Result 2016
CSL Delivers Exceptional Performance

Melbourne, Australia — 16/02/2016

  • Double-digit sales growth in all plasma therapy groups
  • 1st shipment of Privigen® from new facility
  • Seqirus formed – No.2 global influenza vaccines manufacturer
Half Year Report 2016

CSL Limited (ASX:CSL; USOTC:CSLLY) today announced a net profit after tax (NPAT) of US$719 million for the six months ended 31 December 2015, up US$27 million or 4% on a reported basis when compared to the prior comparable period (PCP). Earnings per share (EPS) grew 6%. After excluding financials relating to the recently acquired Novartis influenza vaccines business, underlying1 NPAT grew 7% and EPS grew 9%, at constant currency2.

HIGHLIGHTS

Financial

  • Sales US$3,056 million, up 11% on PCP
    Underlying1 sales up 9% at constant currency2
  • NPAT US$719 million, up 4% on PCP
    Underlying NPAT up 7% at constant currency
  • Earnings per share US$1.55, up 6% on PCP
    Underlying EPS up 9% at constant currency
  • Cashflow from operations US$705 million, up 8% on PCP
  • Interim dividend3 of US$0.58 per share, unfranked for Australian tax purposes, payable on 15 April 2016
    Converted to Australian currency, the interim dividend increased to approximately A$0.81 per share, up ~10% on PCP.

Download this release: 
PDF icon CSL Half Year Results Announcement for 2015/16   (0.2Mb)

Additional resources:
Details about CSL's results are included in the company's 4E statement, investor presentation slides and webcast. More ...

For further information, please contact:

Investors:
  Mark Dehring
  Head of Investor Relations
  CSL Limited
  Phone: +613 9389 3407
  Email: mark.dehring@csl.com.au
Media:
  Sharon McHale
  Senior Director Public Affairs
  CSL Limited
  Phone: +613 9389 3425
  Mobile: +614 0997 8314
  Email: sharon.mchale@csl.com.au




1 Underlying excludes financials relating to the Novartis influenza vaccines business (NVS-IV). NVS-IV was acquired on 31 July 2015.
2 Constant currency removes the impact of exchange rate movements to facilitate comparability of operational performance. See end note (#) for further detail.
3 For shareholders with an Australian registered address, dividends will be paid in A$ at an amount of A$0.814726 per share (at an exchange rate of A$1.4047/US$1.00), and for shareholders with a New Zealand registered address, dividends will be paid in NZD at an amount of NZ$0.874234 per share (at an exchange rate of NZ$1.5073/US$1.00). The exchange rates used are fixed at the date of dividend determination. All other shareholders will be paid in US$. As a result of the ASX’s announced intention to move to a T+2 settlement cycle, CSL’s ex-dividend date for its interim dividend will be 23 March 2016 (previously 22 March 2016)

© 2017 CSL Limited